GR3030046T3 - Method of preparing a radioactive rhenium complex solution. - Google Patents
Method of preparing a radioactive rhenium complex solution.Info
- Publication number
- GR3030046T3 GR3030046T3 GR990401123T GR990401123T GR3030046T3 GR 3030046 T3 GR3030046 T3 GR 3030046T3 GR 990401123 T GR990401123 T GR 990401123T GR 990401123 T GR990401123 T GR 990401123T GR 3030046 T3 GR3030046 T3 GR 3030046T3
- Authority
- GR
- Greece
- Prior art keywords
- benzodiazepines
- cholinesterase
- anxiety
- hypnotic
- sedative
- Prior art date
Links
- 230000002285 radioactive effect Effects 0.000 title 1
- 229910052702 rhenium Inorganic materials 0.000 title 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 title 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 3
- 229940049706 benzodiazepine Drugs 0.000 abstract 3
- 150000001557 benzodiazepines Chemical class 0.000 abstract 3
- 102100033639 Acetylcholinesterase Human genes 0.000 abstract 2
- 108010022752 Acetylcholinesterase Proteins 0.000 abstract 2
- 229940022698 acetylcholinesterase Drugs 0.000 abstract 2
- 230000003001 depressive effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 abstract 2
- 230000000147 hypnotic effect Effects 0.000 abstract 2
- 230000000241 respiratory effect Effects 0.000 abstract 2
- 239000000932 sedative agent Substances 0.000 abstract 2
- 230000001624 sedative effect Effects 0.000 abstract 2
- VLGAHTYYCHWLNI-BHRZLAGCSA-N 1w4l Chemical compound O1C(=C23)C(OC)=CC=C2C=[N+](CCCCCCCCN2C(C4=CC=CC=C4C2=O)=O)CC[C@]23[C@@H]1C[C@@H](O)C=C2 VLGAHTYYCHWLNI-BHRZLAGCSA-N 0.000 abstract 1
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 abstract 1
- 108010053652 Butyrylcholinesterase Proteins 0.000 abstract 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 abstract 1
- 102100032404 Cholinesterase Human genes 0.000 abstract 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 abstract 1
- 208000007101 Muscle Cramp Diseases 0.000 abstract 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 1
- 206010033670 Panic reaction Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000005392 Spasm Diseases 0.000 abstract 1
- 230000001773 anti-convulsant effect Effects 0.000 abstract 1
- 230000000561 anti-psychotic effect Effects 0.000 abstract 1
- 239000001961 anticonvulsive agent Substances 0.000 abstract 1
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- -1 antipsychotic Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 230000000949 anxiolytic effect Effects 0.000 abstract 1
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229960003980 galantamine Drugs 0.000 abstract 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 abstract 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 239000003158 myorelaxant agent Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 208000022610 schizoaffective disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IS3706A IS3706A7 (is) | 1991-05-14 | 1991-05-14 | Notkun á galantamine-hydróbrómíði í geðlæknisfræði |
| DK18292A DK18292D0 (da) | 1992-02-13 | 1992-02-13 | Method of counteracting adverse effects of benzodiazepines |
| PCT/DK1992/000161 WO1992020328A2 (en) | 1991-05-14 | 1992-05-14 | Improvements in benzodiazepine treatment by cholinesterase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR3030046T3 true GR3030046T3 (en) | 1999-07-30 |
Family
ID=36746635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR990401123T GR3030046T3 (en) | 1991-05-14 | 1999-04-23 | Method of preparing a radioactive rhenium complex solution. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US5336675A (el) |
| EP (3) | EP0879596B8 (el) |
| JP (2) | JP3778923B2 (el) |
| AT (2) | ATE336236T1 (el) |
| CA (2) | CA2468449C (el) |
| DE (2) | DE69228928T2 (el) |
| DK (2) | DK0584285T3 (el) |
| ES (2) | ES2129450T3 (el) |
| GR (1) | GR3030046T3 (el) |
| IE (2) | IE990887A1 (el) |
| IS (1) | IS3863A (el) |
| NO (2) | NO308125B1 (el) |
| NZ (1) | NZ242743A (el) |
| PT (1) | PT879596E (el) |
| WO (1) | WO1992020328A2 (el) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994002475A1 (en) * | 1992-07-24 | 1994-02-03 | The Regents Of The University Of California | Drugs that enhance synaptic responses mediated by ampa receptors |
| DE4301782C1 (de) * | 1993-01-23 | 1994-08-25 | Lohmann Therapie Syst Lts | Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit |
| US6323196B1 (en) * | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
| DE19509663A1 (de) | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
| GB9514821D0 (en) * | 1995-07-19 | 1995-09-20 | Sod Conseils Rech Applic | Galanthamine derivatives |
| DE19533772C1 (de) * | 1995-09-12 | 1998-01-02 | Hexal Ag | Tacrin/Selegilin-Pflaster |
| GB9519268D0 (en) * | 1995-09-21 | 1995-11-22 | Chiroscience Ltd | Preparation of alkaloids |
| AT402691B (de) * | 1996-01-26 | 1997-07-25 | Sanochemia Ltd | Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome |
| AT403803B (de) * | 1996-04-19 | 1998-05-25 | Sanochemia Ltd | Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln |
| TW506836B (en) | 1996-06-14 | 2002-10-21 | Janssen Pharmaceutica Nv | Fast-dissolving galanthamine hydrobromide tablet |
| US5736075A (en) * | 1996-10-22 | 1998-04-07 | C.J. Associates, Ltd. | Method of forming a molded product using a freezing step |
| GB9716879D0 (en) * | 1997-08-08 | 1997-10-15 | Shire Int Licensing Bv | Treatment of attention deficit disorders |
| IT1304904B1 (it) | 1998-09-11 | 2001-04-05 | Eisai Co Ltd | Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche |
| CA2345767A1 (en) * | 1998-10-16 | 2000-04-27 | Paul Leonce Irma De Nijs | Therapy for improving cognition |
| CA2351347A1 (en) * | 1998-11-23 | 2000-06-02 | Bonnie Davis | Dosage formulations for acetylcholinesterase inhibitors |
| AU2004242546B2 (en) * | 1998-11-23 | 2008-05-15 | Bonnie Davis | Dosage formulations for acetylcholinesterase inhibitors |
| DE19857716A1 (de) * | 1998-12-15 | 2000-06-21 | Bayer Ag | Neue feste Formulierung von Metrifonat |
| OA11740A (en) * | 1998-12-24 | 2005-05-13 | Janssen Pharmaceutica Nv | Controlled release galantamine composition. |
| DE19906977C1 (de) * | 1999-02-19 | 2000-06-15 | Lohmann Therapie Syst Lts | Desoxypeganin-TTS und seine Verwendung |
| US20050063998A1 (en) * | 1999-10-26 | 2005-03-24 | Francois Marc Karel Jozef | Oral solution containing galantamine and a sweetening agent |
| BR0105563A (pt) * | 2000-03-31 | 2002-04-02 | Sanochemia Pharmazeutika Ag | Derivados e análogos de galantamina |
| CA2310950C (en) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | An efficacious dosage regiment of galantamine that reduces side effects |
| US6673302B2 (en) | 2001-01-24 | 2004-01-06 | Scimed Life Systems, Inc. | Wet processing method for catheter balloons |
| DE10119862A1 (de) * | 2001-04-24 | 2002-11-07 | Hf Arzneimittelforsch Gmbh | Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen |
| CA2358148A1 (en) * | 2001-10-03 | 2003-04-03 | Mold-Masters Limited | A nozzle |
| DE10235556A1 (de) * | 2002-08-03 | 2004-02-19 | Hf Arzneimittelforschung Gmbh | Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums |
| US20040067934A1 (en) * | 2002-10-03 | 2004-04-08 | Parys Wim Louis Julien | Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
| AU2003287433A1 (en) * | 2002-11-01 | 2004-06-07 | Oregon Health And Science University | Treatment of hyperkinetic movement disorder with donepezil |
| AU2004216360B2 (en) * | 2003-02-27 | 2009-09-17 | Eisai R & D Management Co., Ltd. | Pharmaceutical composition for treatment of drug dependence |
| US7297691B2 (en) | 2003-08-13 | 2007-11-20 | Janssen Pharmaceutica N.V. | Treatment of sleep disorders with cholinesterase inhibitors |
| DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
| BG65658B1 (bg) * | 2003-11-13 | 2009-05-29 | "Софарма" Ад | Комбиниран лекарствен продукт на основата на галантамин |
| DE10354893B4 (de) * | 2003-11-24 | 2011-03-10 | Hf Arzneimittelforschung Gmbh | Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen |
| CA2551946A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Immediate, controlled and sustained release formulations of galantamine |
| WO2005065662A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Solid dosage formulations of galantamine |
| WO2005115471A2 (en) * | 2004-05-27 | 2005-12-08 | Neurocure Ltd. | Methods and compositions for treatment of nicotine dependence and dementias |
| ES2662868T3 (es) * | 2004-09-24 | 2018-04-10 | University Of Maryland, Baltimore | Procedimiento para el tratamiento de una intoxicación por una sustancia organofosforada |
| US9132135B2 (en) | 2004-09-24 | 2015-09-15 | University Of Maryland, Baltimore | Method of treating organophosphorous poisoning |
| EP2066355A2 (en) * | 2006-09-19 | 2009-06-10 | Braincells, Inc. | Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis |
| CN101190330A (zh) * | 2006-11-30 | 2008-06-04 | 深圳市鼎兴生物医药技术开发有限公司 | 胆碱酯酶在拮抗速激肽药物中的应用 |
| US8110226B2 (en) * | 2007-07-20 | 2012-02-07 | Mylan Pharmaceuticals Inc. | Drug formulations having inert sealed cores |
| EP2030610A1 (en) * | 2007-08-31 | 2009-03-04 | Archimedes Development Limited | Non-aqueous pharmaceutical compositions |
| JP5539875B2 (ja) * | 2007-08-31 | 2014-07-02 | アルキメデス・デベロップメント・リミテッド | 非水性医薬組成物 |
| CL2008003507A1 (es) * | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
| IL301562A (en) * | 2020-10-01 | 2023-05-01 | Univ Leland Stanford Junior | Methods and systems for modifying empathy by modulating type 2 theta oscillations |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| WO1988008708A1 (en) * | 1987-05-04 | 1988-11-17 | Bonnie Davis | Compounds for the treatment of alzheimer's disease |
| IL87861A0 (en) * | 1987-10-05 | 1989-03-31 | Pfizer | 4-aminopyridine derivatives |
| JP2699511B2 (ja) * | 1988-01-29 | 1998-01-19 | 武田薬品工業株式会社 | 置換アミン類 |
| JP2931986B2 (ja) * | 1989-02-17 | 1999-08-09 | 武田薬品工業株式会社 | アラルキルアミン誘導体 |
| KR940003491B1 (ko) * | 1989-08-10 | 1994-04-23 | 리히터 게데온 베기에스제티 기아르 알.티 | 4,4-이중 치환된 피페리딘 유도체와 그 제조방법 및 상기 화합물을 함유하는 약제학적 조성물 |
| DE3927049A1 (de) * | 1989-08-16 | 1991-02-21 | Sandoz Ag | Halogenalkyl-phenyl-ketone und deren hydrate, ihre herstellung und verwendung |
-
1992
- 1992-02-28 US US07/842,322 patent/US5336675A/en not_active Expired - Lifetime
- 1992-05-14 CA CA002468449A patent/CA2468449C/en not_active Expired - Lifetime
- 1992-05-14 CA CA002103022A patent/CA2103022C/en not_active Expired - Lifetime
- 1992-05-14 DK DK92917377T patent/DK0584285T3/da active
- 1992-05-14 DE DE69228928T patent/DE69228928T2/de not_active Expired - Fee Related
- 1992-05-14 AT AT98201818T patent/ATE336236T1/de not_active IP Right Cessation
- 1992-05-14 DK DK98201818T patent/DK0879596T3/da active
- 1992-05-14 NZ NZ242743A patent/NZ242743A/en not_active IP Right Cessation
- 1992-05-14 EP EP98201818A patent/EP0879596B8/en not_active Expired - Lifetime
- 1992-05-14 DE DE69233648T patent/DE69233648T2/de not_active Expired - Fee Related
- 1992-05-14 JP JP51011192A patent/JP3778923B2/ja not_active Expired - Fee Related
- 1992-05-14 EP EP92917377A patent/EP0584285B1/en not_active Expired - Lifetime
- 1992-05-14 PT PT98201818T patent/PT879596E/pt unknown
- 1992-05-14 ES ES92917377T patent/ES2129450T3/es not_active Expired - Lifetime
- 1992-05-14 AT AT92917377T patent/ATE178791T1/de not_active IP Right Cessation
- 1992-05-14 IS IS3863A patent/IS3863A/is unknown
- 1992-05-14 WO PCT/DK1992/000161 patent/WO1992020328A2/en active IP Right Grant
- 1992-05-14 EP EP92610035A patent/EP0515302A1/en active Pending
- 1992-05-14 ES ES98201818T patent/ES2270493T3/es not_active Expired - Lifetime
- 1992-07-01 IE IE19990887A patent/IE990887A1/en not_active IP Right Cessation
- 1992-07-01 IE IE154892A patent/IE921548A1/en not_active IP Right Cessation
-
1993
- 1993-11-12 NO NO934103A patent/NO308125B1/no unknown
-
1994
- 1994-08-22 US US08/292,230 patent/US5589475A/en not_active Expired - Lifetime
-
1995
- 1995-06-05 US US08/461,849 patent/US5633238A/en not_active Expired - Fee Related
-
1998
- 1998-08-27 NO NO19983939A patent/NO322137B1/no unknown
-
1999
- 1999-04-23 GR GR990401123T patent/GR3030046T3/el unknown
-
2002
- 2002-02-15 JP JP2002082084A patent/JP2002326959A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GR3030046T3 (en) | Method of preparing a radioactive rhenium complex solution. | |
| EP0515301A3 (en) | Improvements in benzodiazepine treatment by cholinesterterase inhibitors | |
| HUT75645A (en) | Tetrahydropyridine-(or 4-hydroxypiperidine)alkylazole derivatives | |
| GB9921150D0 (en) | Therapeutic agents | |
| IL78790A0 (en) | Oxadiazolyl imidazobenzodiazepine compound,pharmaceutical compositions containing said compound,method of preparing said compound and method of treating a central nervous system ailment | |
| ATE159018T1 (de) | Pyrrolo(2,3-d>azepinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen | |
| PT83924A (en) | Process for the preparation of tricyclic pyridazopyridone derivatives and of pharmaceutical compositions containing the same | |
| EP0462468A3 (en) | 9-amino-2-phenylbicyclo(3.3.1)nonane and 9-amino-2-phenylbicyclo(3.3.1)-non-2-ene and therapeutic agents containing them | |
| HUT68684A (en) | Process for producing intermediates of compounds with antifolate activity | |
| CY2003B1 (en) | Anticonvulsant triazolo(4,5-C) pyridine derivatives |